A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder

Trial Profile

A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 01 Aug 2013 Results published in the Journal of Clinical Psychiatry.
    • 01 Aug 2013 Primary endpoint 'Yale-Global-Tic-Severity-Scale' has been met according to results published in the Journal of Clinical Psychiatry.
    • 22 Oct 2008 Actual start date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top